China
Africa
Explore chapters and articles related to this topic
Age-Related Macular Degeneration
Published in Ching-Yu Cheng, Tien Yin Wong, Ophthalmic Epidemiology, 2022
Jost B. Jonas, Songhomitra Panda-Jonas
From 1990 onwards, the percentage of individuals blind or visually impaired due to AMD in comparison to the total number of blind or visually impaired people has continuously increased, reflecting the success in reducing the amount of blindness and vision impairment due to cataract and refractive error. The findings obtained by the Vision Loss Expert Group revealed that in 2015 AMD was globally the fourth most common cause of blindness and the third most common cause of MSVI. It shows the future importance of AMD for public health. If one anticipates that treatment modalities may also become available for non-exudative forms of AMD, for which currently no treatment modalities exist, the treatment costs for AMD may increase in future. Several therapies directed against geographic atrophy as one form of late AMD are currently under development, and their potential impact on the incidence of blindness due to geographic atrophy of the macula will need to be evaluated in future studies.
Getting deep in the pain
Published in Paul M.W. Hackett, Christopher M. Hayre, Handbook of Ethnography in Healthcare Research, 2020
Geographic atrophy (GA) is a disease that affects people’s sight by consistently narrowing their field of vision, drastically and steadily decreasing their quality of life. People suffering from GA are overwhelmed by a sense of loss and estranged from what was once familiar; they encounter countless limitations and estrangement because the illness entails relearning how to move, act, and be perceived in the world.
Practical approach to macular translocation with 360° peripheral retinectomy
Published in A Peyman MD Gholam, A Meffert MD Stephen, D Conway MD FACS Mandi, Chiasson Trisha, Vitreoretinal Surgical Techniques, 2019
John P Denny, Mark T Cahill, Sharon F Freedman, Cynthia A Toth
Severe vision loss in ARMD may also be due to geographic atrophy. Although MT360 for eyes with geographic atrophy has resulted in early improvement in visual acuity,24–;26 geographic atrophy has later recurred under the new fovea in numerous cases, which has led to caution in considering this surgery for geographic atrophy.
A clinical perspective on the expanding role of artificial intelligence in age-related macular degeneration
Published in Clinical and Experimental Optometry, 2022
Himeesh Kumar, Kai Lyn Goh, Robyn H Guymer, Zhichao Wu
There are no treatments available to slow or prevent progressive vision loss for those who develop geographic atrophy, nor are there specific interventions available for individuals with the early stages of disease to slow or prevent progression to late AMD. Instead, management of the early stages of AMD is limited to lifestyle modification and use of supplements.35,36 However, ongoing monitoring of individuals with geographic atrophy is vital to provide an opportunity for disease counselling, ensure vision is suitable for driving, and surveillance for the development of choroidal neovascularisation.32 As atrophy progresses and has a greater impact on vision, continuing review can help determine when referral to low-vision patient support services is required.32,37 More recently, with clinical trials offering potential treatments for geographic atrophy, a clinical review creates the opportunity for practitioners to identify and refer interested individuals, who may be eligible, to participate in such trials.
The Role of Retinal Plasticity in the Formation of Irreversible Retinal Deformations in Age-Related Macular Degeneration
Published in Current Eye Research, 2022
Daria Peretiahina, Konstantin Shakun, Vadym Ulianov, Nadiia Ulianova
Age-related macular degeneration (AMD) is the dominant cause of irreversible blindness among adults in developed countries, affecting approximately one in eight people aged 60 years or older.1 Approximately 200 million people worldwide currently have AMD problems, and the number is expected to grow, approaching 300 million by 2040.2 Progression of the disease is accompanied by significant loss of central vision due to the development of neovascularization or geographic atrophy. Namely, neovascular AMD (nAMD) is characterized by the onset of choroidal neovascularization with the gradual spread of newly formed vessels through the Bruch’s membrane under the retinal pigment epithelium (RPE) and then into the subretinal space, leading to RPE detachment, intraretinal and/or subretinal fluid accumulation, affecting the central vision dramatically.
Association of Ocular Antihypertensive Medications and the Development and Progression of Age-related Macular Degeneration in a U.S. Insurance Claims Database
Published in Current Eye Research, 2021
Emily A. Eton, Thomas J. Wubben, Cagri G. Besirli, Sophia Y. Wang
Age-related macular degeneration (AMD) is aleading cause of blindness in industrialized nations, affecting 6.5% of Americans over the age of 40 and estimated to impact 200million patients globally.1–4 Additionally, advanced AMD is associated with increased rates of depression and functional disability among the elderly.5 AMD is classified as either nonexudative or exudative, with the exudative variant being an advanced form characterized by the presence of choroidal neovascularization. Geographic atrophy represents another form of advanced AMD characterized by irreversible retinal pigment epithelium, photoreceptor, and choriocapillaris loss,6 leading to significant rates of blindness and visual disability.7 The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has vastly improved the ability to manage exudative AMD, but there remains an unmet need for therapeutics in nonexudative and exudative AMD, and associated geographic atrophy.